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The growth of both normal and malignant 
  tissues depends on the concomitant growth of 
their vascular supply (1–3). During immune 
responses, lymph nodes grow rapidly, and the 
enlargement is accompanied by growth of the 
blood vasculature (4–7). Recent studies have 
begun to delineate the mechanisms that regu-
late vascular growth in tumors and in several 
physiologic processes, and these experiments 
have led to the development of drugs that tar-
get vascular growth (http://www.cancer.gov/
clinicaltrials/developments/anti-angio-table; for 
review see reference 8). In contrast, the regula-
tion of vascular growth in lymph nodes during 
an immune response and the potential utility of 
antiangiogenic therapies as immune modulators 
are not well understood.
Blood vessels of the lymph node are critical 
for the delivery of oxygen, nutrients, and cells. 
The functional importance of this delivery is 
demonstrated by the rapid necrosis of lymph 
nodes upon ablation of the arterial vessels that 
feed the node (9). High endothelial venules 
(HEVs) are segments of postcapillary venules 
and are characterized by specialized cuboidal 
endothelial cells that express the chemokines 
and adhesion molecules needed for extravasa-
tion of cells into the parenchyma of the lymph 
node (10). The importance of the HEV-medi-
ated cell delivery is underscored by the reduced 
lymph node cellularity and impaired effi   ciency 
of immune responses in mice defi  cient in mol-
ecules that mediate lymphocyte–HEV inter-
actions (11–13).
Several studies performed 30–40 yr ago 
established that there is a dramatic increase 
in the vascularity of lymph nodes undergoing 
  immune responses. Dye perfusion and micro-
angiographic studies revealed a cortical capil-
lary dilatation that occurred by the fi  rst  day 
after stimulation (5) and that was associated 
with increased vascular permeability (4, 7). 
Within days, the vasculature appeared to un-
dergo growth, and HEVs showed progressive 
lengthening and arborization (7). In the same 
time frame, capillary networks in both the 
  cortex and medulla became more prominent 
(5, 7). Mitotic HEV endothelial cells were de-
tectable as early as day 2, and endothelial cell 
tritiated thymidine uptake was also seen during 
the fi  rst week, indicating that the addition of 
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endothelial cells rather than vasodilation alone contributed 
to the increased vascularity (4, 7). Functional assays of blood 
fl   ow were consistent with morphologic fi  ndings,  demon-
strating a transient increase in fl  ow within the fi  rst day fol-
lowed by a sustained increase corresponding to the observed 
vascular growth (14).
The regulation of lymph node blood vascular growth is 
not well understood, although lymphocytes and vascular endo-
thelial growth factor (VEGF) have been implicated. A study 
showed that radiation-sensitive cells mediated the hypervas-
cularity seen after lymph node stimulation (6). T cells (15, 16) 
and mitogen-stimulated leukocytes (17, 18) can produce an-
giogenic factors. Additionally, B cells can express the angio-
genic factor VEGF (19, 20), and the expression of C-myc in 
B cells can lead to lymph node blood vascular and lymphatic 
growth (19). HEV expansion is also inducible by Toll-like 
receptor stimulation (21). VEGF expression is up-regulated 
in lymph nodes from patients with angioimmunoblastic T cell 
lymphoma (22, 23) and Castleman’s disease (23, 24), which 
are two lymphoproliferative diseases that are characterized by 
increased vascularization of aff  ected lymph nodes. Further-
more, lymph node metastasis of a VEGF-overexpressing skin 
tumor resulted in blood vessel expansion (25).
DCs are the professional antigen-presenting cells in lym-
phoid tissues. At the initiation of an immune response, DCs 
that are stimulated at the periphery undergo maturation and 
travel via aff  erent lymphatics to the draining lymph node (26). 
The DCs localize to the paracortex in the vicinity of HEVs, 
where they have the potential to interact with T cells as the 
lymphocytes extravasate through the HEV (27, 28). Recent 
studies have implicated DCs in the stimulation of blood ves-
sel growth at sites of chronic infl  ammation and in tumors. 
DCs at sites of infl   ammation have been noted to express 
VEGF (29), and cultured mouse and human DCs can also 
express VEGF (30–32). Plasmacytoid DCs have also been 
implicated (33). The role of DCs in regulating lymph node 
vascular growth is unknown.
We are interested in better understanding the regulation 
of lymph node vascular growth. Our study characterizes endo-
thelial cell growth and proliferation in draining lymph nodes 
and reveals a novel role for DCs in initiating lymph node 
vascular growth.
RESULTS
Immunization induces endothelial cell proliferation 
in draining lymph nodes
Subcutaneous immunization with OVA in CFA (OVA/
CFA) induced a robust and rapid growth specifi  cally in the 
draining lymph nodes (Fig. 1 A). To check whether our im-
munization system yielded the increased vascularity docu-
mented in nodes stimulated by other methods (5–7), we 
injected FITC-labeled tomato lectin, which binds to the lu-
minal surface of blood vessels (34). Thick sections of the 
nodes showed that the vasculature appeared to expand with 
Figure 1.  Growth of vascularity and of endothelial cells in the 
draining lymph node. Mice were immunized with OVA/CFA on the upper 
back and killed at the indicated times. (A) Total cell counts of draining 
brachial and nondraining inguinal (Ing) lymph nodes. (B) Vascularity of 
brachial lymph nodes at day 5. (A and B) n = 3 mice. (C) FACS plot show-
ing the CD45negCD31hi endothelial cell population (R1). (D) Endothelial cell 
count in the same lymph nodes as in A. (E) Endothelial cell (EC) prolifera-
tion in brachial lymph nodes over the preceding 48 h at days 2 and 5 as 
measured by the percentage of endothelial cells that incorporated BrdU. 
(F) Endothelial cell proliferation in brachial lymph nodes over the preceding 
24 h on days 1, 2, and 3. (E and F) Each symbol represents one mouse, 
and results are representative of experiments performed four times. 
(G) Immunohistochemical stain for PNAd (blue), BrdU (pink), and CD45 
(brown) in a day 3 draining lymph node to show BrdU uptake by PNAd+ 
HEV endothelial cells. (H) Percentage of HEVs in brachial lymph nodes 
that have at least one BrdU+PNAD+ cell. n ≥ 4 mice for each time point. 
(A, B, D, and H) *, P < 0.05; **, P < 0.01 with the Student’s t test com-
pared with PBS-injected controls. (A, D, E, F, and H) Closed symbols repre-
sent samples from immunized mice, and open symbols represent samples 
from PBS-injected control mice. Error bars represent SD.JEM VOL. 203, August 7, 2006  1905
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the lymph node upon immunization, although the density of 
vessels per area did not appear to increase (Fig. S1, available 
at http://www.jem.org/cgi/content/full/jem.20052272/DC1). 
To quantitate the apparent growth, thin sections were cut 
through the thickness of the labeled nodes, and the FITC+ 
surface area was measured as a correlate of vascularity. The 
vascular density as measured by the percentage of total area 
covered by FITC label did not increase with immunization 
(3.8 ± 1.7% for PBS and 2.5 ± 0.6% for OVA/CFA; P = 
0.22 with the Student’s t test). However, the total pixel count 
doubled by day 5 (Fig. 1 B), indicating that the stimulated 
lymph nodes had increased vascularity.
We used fl  ow cytometry to assess whether this increased 
vascularity refl  ected an increase in endothelial cell numbers. 
Endothelial cells are CD45neg and CD31hi (35–37), and this 
population was easily distinguishable by fl  ow  cytometry 
(Fig. 1 C). The identity of these cells as endothelial cells was 
confi  rmed by their coexpression of the endothelial markers 
CD34 (38) and vascular endothelial cadherin (reference 39; 
and unpublished data). Endothelial cell numbers increased 
over time in the draining lymph nodes (Fig. 1 D). However, 
in contrast to the increase in lymph node cellularity within 
1 d of immunization (Fig. 1 A), endothelial cell numbers did 
not increase measurably until day 3. Like lymph node size, 
endothelial cell numbers plateaued at day 7 (Fig. 1 D). Analy-
sis of the relative number of blood vessel versus lymphatic 
vessel endothelial cells (as indicated by staining for LYVE-1, 
a lymphatic endothelial marker; reference 40) indicated that 
the majority of endothelial cells (85–90%) were blood vas-
cular endothelial cells and that both populations expanded 
(unpublished data).
To assess whether the increased endothelial cell numbers 
were associated with cell proliferation, we examined BrdU 
uptake. In mice that were given BrdU for 2 d, increased 
BrdU uptake was detectable by day 2, indicating that cell 
proliferation had started somewhere within the fi  rst 48 h after 
immunization. The rate of BrdU uptake continued to in-
crease between days 2 and 5 (Fig. 1 E). To refi  ne our under-
standing of when the endothelial cell growth initiated, we 
pulsed with BrdU for only 24 h. Clearly detectable increases 
in BrdU uptake occurred between days 1 and 2, indicating 
that the signals that induced endothelial cell proliferation 
were active within a day after immunization (Fig. 1 F).
BrdU+ endothelial cells were detected in blood vessels in 
tissue sections. Because individual HEV cells are large, easily 
detected, and identifi  able by staining for the MECA-79 anti-
gen PNAd (Fig. 1 G; reference 41), we limited our examina-
tion to PNAd+ HEVs and scored the number of BrdU+ 
HEVs over time. This analysis showed a trend similar to that 
found for total endothelial cells by fl  ow cytometry: an in-
crease in BrdU uptake at day 2 and continued increase 
through day 5 (Fig. 1 H). Collectively, these results indicated 
that endothelial cells in draining lymph nodes were rapidly 
induced to undergo proliferation and that inductive signals 
acted early.
DCs regulate endothelial cell proliferation
One of the initial events upon a peripheral challenge is the 
maturation and migration of DCs to the draining lymph 
node (26). To test the importance of DCs in the induction of 
endothelial cell proliferation, we asked whether immuniza-
tion with OVA/CFA could induce lymph node endothelial 
cell proliferation when DCs were depleted. CD11c-DTR 
(diphtheria toxin [DT] receptor) mice express DTR on 
CD11c+ cells, and treatment with DT selectively depletes 
CD11c+ cells within hours (42). Immunization of CD11c-
DTR mice without DT treatment resulted in lymph node 
endothelial cell proliferation at levels similar to that in wild-
type mice (Fig. 2 A). We depleted local DCs by injecting DT 
into the footpads and then asked about the eff  ect of OVA/
CFA immunization. DT depleted the majority but not all of 
the CD11c+MHCII+ DCs in the lymph nodes of CD11c-
DTR mice (Fig. 2 B). The depletion was associated with a 
signifi  cant reduction in both lymph node size (Fig. 2 C) and 
endothelial cell proliferation (Fig. 2 D) in the draining lymph 
nodes. Plotting the endothelial cell proliferation rate as a 
function of the number of remaining CD11c+MHCII+ cells 
in the DT-treated CD11c-DTR mice further highlighted 
Figure 2.  CD11c+ cells are important for lymph node endothelial 
cell proliferation. (A) Endothelial cell proliferation on day 2 in wild-type 
or CD11c-DTR (DTR) mice upon immunization with OVA/CFA. n = 3 mice 
for each condition. *, P < 0.01; P = 0.76 for immunized wild-type versus 
immunized DTR mice. (B–D) Effects of DT treatment in immunized mice 
on CD11c+MHCII+ DCs per lymph node (B), lymph node size (C), and 
  endothelial cell (EC) proliferation (D). n = 5 mice for each condition. 
(E) Plot of endothelial cell proliferation as a function of the number of 
CD11c+MHCII+ DCs remaining in draining lymph nodes of the DT-treated 
CD11c-DTR mice. (B–D) *, P < 0.03; **, P < 0.004 with the Student’s t test. 
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the correlation between endothelial cell proliferation and 
DC numbers (Fig. 2 E). These results suggested that DCs 
were critical mediators of the OVA/CFA-induced endothe-
lial cell proliferation.
We examined whether injection at the periphery of ma-
ture migration-competent DCs was suffi   cient to trigger en-
dothelial cell proliferation. BM-derived DCs (BMDCs) were 
matured with LPS to generate migration-competent mature 
DCs. Consistent with a previous study (43), the injection of 
LPS-matured BMDCs into the footpad led to an accumula-
tion of BMDCs in the popliteal lymph node (Fig. 3 A) and 
a corresponding growth of the lymph node (Fig. 3 B). We 
found a robust proliferative response of endothelial cells (Fig. 
3 C) with a concomitant increase in endothelial cell numbers 
(Fig. 3 D). This eff  ect was titratable; decreasing the number 
of BMDCs transferred led to fewer BMDCs in the draining 
lymph nodes and smaller increases in lymph node size, endothe-
lial BrdU uptake, and endothelial cell numbers (Fig. 3, A–D). 
Similarly, there was a correlation between the number of 
BMDCs that accumulated and the rate of endothelial cell 
proliferation over time (Fig. 3, E and F).
The CFSE+ cells that accumulated in the lymph nodes 
were CD11c+MHCIIhi, which is consistent with a mature 
DC phenotype (Fig. S3 C, available at http://www.jem.org/
cgi/content/full/jem.20052272/DC1). However, granulo-
cytes were a major contaminant (44) in our BMDC cultures, 
comprising 15–25% of cells. To further establish that DCs 
drive lymph node vascular growth, we further enriched for 
DCs by depleting granulocytes. The injection of 750,000 
granulocyte-depleted BMDCs led to endothelial cell prolif-
eration that was similar to the injection of 1 million unfrac-
tionated BMDCs (Fig. 3 G). In contrast, injecting the 
equivalent of the 25% of cells that remained after the deple-
tion of CD11c+ cells stimulated only low levels of endo-
thelial cell proliferation (Fig. 3 G). Thus, DCs are able to 
stimulate endothelial cell proliferation, and their endothelial 
cell–stimulating activity accounted for most of the activity in 
unfractionated BMDCs. Additionally, the DC-enriched 
(granulocyte-depleted BMDC) fraction induced higher levels 
of endothelial cell proliferation than the DC-depleted frac-
tion when equal numbers of cells (500,000) from each frac-
tion were injected (15 ± 6% proliferation induced by 
DC-enriched BMDCs and 9 ± 3% proliferation induced by 
DC-depleted cells; P < 0.03; n = 10). This suggested that 
DCs were specifi  cally able to induce higher levels of lymph 
node endothelial cell proliferation.
To establish that the DC-induced endothelial cell prolifera-
tion was not the result of LPS carryover, we examined BMDCs 
that were not treated with LPS. 10–20% of the cultured DCs 
spontaneously develop a mature phenotype without LPS stim-
ulation (unpublished data). Untreated BMDCs also migrated 
to draining nodes and induced endothelial cell growth, albeit at 
lower levels than with LPS-treated cells (Fig. S2, A–C; avail-
able at http://www.jem.org/cgi/content/full/jem.20052272/
DC1). Untreated BMDCs depleted of granulocytes also in-
duced endothelial cell proliferation, whereas CD11c-depleted 
cells were less able to stimulate endothelial cell proliferation 
(Fig. S2 D). These results suggested that the stimulation of vas-
cular growth by the LPS-matured cultured DCs was not caused 
by carryover of the LPS used to stimulate the DCs.
Figure 3.  DCs induce endothelial cell proliferation. (A–D) Indicated 
numbers of CFSE-labeled BMDCs were injected into the footpad, and mice 
were examined at day 5. Number of CFSE+ BMDCs (A), number of total 
cells (B), endothelial cell (EC) proliferation (C), and number of endothelial 
cells (D) in draining lymph nodes. Each symbol represents one mouse. 
Bars represent the mean values. (E and F) Number of CFSE+ BMDCs 
(E) and endothelial cell BrdU uptake (F) in draining lymph nodes over time 
after the injection of 106 BMDCs. Each symbol represents one mouse. 
Closed circles represent draining popliteal lymph nodes, and open tri-
angles represent nondraining brachial lymph nodes from the same mice. 
(A–F) Results are representative of at least three separate experiments. 
(G) Endothelial cell BrdU uptake upon injection of unseparated BMDCs 
(All), granulocyte-depleted BMDCs (Gr-1−), or DC-depleted BMDCs 
(CD11c−). n ≥ 3 mice for each condition. *, P < 0.05 with the Student’s 
t test. (H) Endothelial cell count at day 5 in draining popliteal lymph 
nodes of mice injected with PBS or with 106 CD11c+ or CD11c− cells iso-
lated from the spleen. n ≥ 8. *, P < 0.00005 with the Student’s t test. 
Error bars represent SD. JEM VOL. 203, August 7, 2006  1907
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We assessed whether DCs purifi  ed directly from tissue 
were also capable of stimulating lymph node vascular growth. 
CD11c+ DCs were purifi  ed from mouse spleens by mag-
netic selection. The CD11c+ but not the CD11c− fraction 
induced endothelial cell growth (Fig. 3 H). This growth was 
accompanied by increased endothelial cell BrdU uptake 
(unpublished data).
Cells from ovarian tumors with DC characteristics have 
been shown to take on an endothelial cell phenotype (31, 
45). Therefore, we examined whether the endothelial cell 
growth was the result of BMDCs trans-diff  erentiating into 
endothelial cells. By fl  ow cytometry, the CFSE-labeled pop-
ulation retained the CD11c+MHCIIhi DC phenotype and 
did not acquire the CD45−CD31hi phenotype of endothe-
lial cells (Fig. S3, A–E). We also asked whether the CFSE-
  labeled DCs were incorporated into HEV walls. In frozen 
sections, CFSE+ BMDCs were located in the T zone in the 
vicinity of HEVs but were not incorporated into the HEV 
walls (Fig. S3, F and G). These data suggested that the in-
jected DCs are not trans-diff  erentiating into endothelial cells 
and are functioning to drive the proliferation of endogenous 
endothelial cells. Collectively, our data indicated that DCs 
can drive lymph node vascular growth.
Lymphocytes are not required for DC-induced endothelial 
cell proliferation
In the lymph node, DCs can stimulate T and B cells (26). We 
asked whether DC-induced endothelial cell proliferation was 
dependent on lymphocytes and examined RAG1−/− mice 
defi   cient in mature lymphocytes (46). RAG1−/− lymph 
nodes had decreased cellularity and a decreased basal level of 
endothelial cell proliferation (Fig. 4, A, B, and D). Despite 
the lack of lymphocytes that would be expected to contribute 
to the lymph node enlargement upon stimulation, RAG1−/− 
lymph nodes grew in size and cellularity after BMDC transfer 
(not depicted and Fig. 4, A and B). Fewer BMDCs accumu-
lated in the RAG1−/− lymph nodes, and the overall magni-
tude of the induced endothelial cell proliferation was lower 
in RAG1−/− mice    (Fig. 4, C and D), but BMDC injection 
stimulated increased endothelial cell proliferation in both 
wild-type and RAG1−/− mice. Similar results were obtained 
using granulocyte-depleted BMDCs (unpublished data). 
Figure 4.  DC-induced endothelial cell proliferation in RAG1−/− 
mice. BMDCs were injected into wild-type or RAG1−/− recipients and 
examined on day 2. (A and B) Lymph node cellularity in wild-type (A) and 
RAG1−/− (B) mice. (C) Number of CFSE+ cells in draining lymph nodes. 
(D) Endothelial cell (EC) BrdU uptake. n ≥ 6 mice for each condition. 
*, P < 0.05; **, P < 0.01 with the Student’s t test. Error bars represent SD.
Figure 5.  Role of cell recruitment in endothelial cell proliferation. 
Indicated numbers of CFSE+ BMDCs were injected into anti–L-selectin– 
(α-L-sel) or control antibody (IgG)-treated recipients and examined on 
day 2. (A) CFSE+ BMDC accumulation (left) and endothelial cell BrdU up-
take (right) upon injection of equal numbers of BMDCs. Each symbol rep-
resents one mouse, and data are representative of three similar 
experiments. (B–D) BMDC numbers were adjusted to obtain similar levels 
of BMDC accumulation in control and anti–L-selectin–treated mice. 
CFSE+ BMDC accumulation (B), lymph node cell counts (C), and endothe-
lial cell (EC) BrdU uptake (D) in draining lymph nodes. n ≥ 9 mice for 
each condition. Bars represent the mean values. **, P < 0.007. Error bars 
represent SD.1908  LYMPH NODE VASCULAR GROWTH | Webster et al.
These results indicated that DCs could stimulate endothelial 
cell proliferation in the absence of lymphocytes.
DC-induced endothelial proliferation is modulated 
by recruited cells
Our results pointed toward a potential relationship between 
lymph node cellularity and endothelial cell proliferation (Figs. 
1–4). OVA/CFA or BMDC injection induced lymph node 
growth within 1 d (Fig. 1; reference 43), suggesting that DCs 
may induce growth of the lymph node before they induce 
endothelial cell proliferation. The growth in lymph node cel-
lularity precedes the proliferation of activated lymphocytes 
and is caused, at least in part, by recruitment of cells from the 
circulation (47), and we considered the possibility that cell 
recruitment mediated DC-induced endothelial cell prolifera-
tion. Leukocytes require L-selectin for entry into peripheral 
lymph nodes via the HEV (48), so we blocked cell entry with 
anti–L-selectin and examined the level of endothelial cell 
proliferation at day 2. At that time point, anti–L-selectin 
  antibody is present at saturating levels (Fig. S4, available 
at http://www.jem.org/cgi/content/full/jem.20052272/DC1). 
The L-selectin blockade unexpectedly resulted in the de-
creased accumulation of CFSE+ BMDCs within the lymph 
node (Fig. 5 A, left), which was associated with a reduced 
stimulation of endothelial cell proliferation (Fig. 5 A, right). 
To better examine the eff  ects of L-selectin blockade down-
stream of BMDC accumulation, we reduced the number 
of BMDCs transferred into control recipients to obtain simi-
lar levels of BMDC accumulation in the nodes of the con-
trol and anti–L-selectin–treated mice (Fig. 5 B). L-selectin 
  blockade caused a progressive reduction in lymph node size 
over the course of 2 d (unpublished data), as cells were 
blocked from entering but likely were continuing to exit 
the lymph node via eff  erent lymphatics. By day 2, the num-
ber of cells in the stimulated lymph nodes of the anti–
L-  selectin–treated mice had dropped below the baseline 
cellularity of lymph nodes in control mice that did not receive 
BMDCs (Fig. 5 C). When compared with the nodes of 
  control mice that had been injected with BMDCs, the nodes 
in the anti–L-selectin–treated mice had a reduced rate of 
  endothelial cell proliferation (Fig. 5 D), suggesting that the 
recruitment of cells from the bloodstream in an L-selectin–
dependent   manner mediated at least part of the DC-induced 
endothelial proliferation.
HEV endothelial cell growth and association with increased 
cell entry
HEVs in the lymph node are critical for the entry of cells 
from the circulation. We examined the growth regulation of 
HEV endothelial cells and asked whether HEV growth was 
associated with increased cell entry. OVA/CFA induced the 
proliferation of HEV endothelial cells (Figs. 1 H and 6 A). 
Remarkably, in the CD11c-DTR mice depleted of DCs, 
PNAd+ cell proliferation on average remained relatively 
  intact, whereas PNAd− cell proliferation was dramatically 
  abrogated (Fig. 6 A). However, when endothelial cell 
  proliferation was plotted as a function of the number of re-
maining CD11c+MHCII+ cells, both PNAd+ and PNAd− 
cells showed a dose-response relationship with the number of 
DCs, suggesting that DCs regulated the proliferation rate of 
both populations (Fig. 6 B).
We examined whether DCs were suffi   cient to drive HEV 
proliferation. Injection of either unfractionated or Gr-1–
  depleted BMDCs stimulated similar increases in HEV prolif-
eration (Fig. 6 C), and, by day 5, PNAd+ endothelial cells 
had expanded in numbers (Fig. 6 D). Collectively, these re-
sults were consistent with the notion that DCs regulated 
HEV endothelial cell growth.
We transferred CFSE-labeled lymphocytes to examine 
cell entry into the draining lymph nodes. Cell recruitment 
increases even within 1 d of BMDC injection (47), suggest-
ing that HEV endothelial cells may be activated to express 
more chemoattractive and cell adhesion molecules (49, 50) at 
Figure 6.  HEV endothelial cell proliferation and increased lympho-
cyte entry. (A) Proliferation rate of PNAd+ and PNAd− endothelial cells 
(ECs) in wild-type or CD11c-DTR mice that were treated with DT and im-
munized with OVA/CFA. *, P < 0.01 with the Student’s t test compared 
with PNAd− endothelial cell proliferation in immunized wild-type mice. 
(B) PNAd+ and PNAd− endothelial cell proliferation plotted as a function 
of the remaining CD11c+MHCII+ cells in the draining lymph nodes of 
CD11c-DTR mice. (C) PNAd+ endothelial cell proliferation at day 2 in mice 
injected with 500,000 BMDCs. BMDCs are unfractionated (All) or enriched 
for DCs (granulocyte-depleted; Gr-1−). n ≥ 6 mice for each condition. 
(D) PNAd+ endothelial cell numbers at day 5 after BMDC injection. n = 4. 
(E) T cell entry into lymph nodes that were stimulated 1 or 8 d before the 
intravenous transfer of CFSE-labeled splenocytes. Each symbol represents 
one mouse. Bars represent the mean values. Representative of three 
  separate experiments. *, P < 0.01 with the Student’s t test. Error bars 
represent SD. JEM VOL. 203, August 7, 2006  1909
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this time. Because any increased cell recruitment via the HEV 
could refl  ect either endothelial cell activation or an increased 
number of endothelial cells, we looked at day 1 to assess lym-
phocyte entry via HEVs that were potentially activated but 
had not yet proliferated and compared it with entry at day 8, 
when endothelial cells had undergone proliferation and 
  endothelial cell numbers had increased. CD4+ T cell entry 
into the draining popliteal lymph nodes showed greater entry 
on day 8 than on day 1 (Fig. 6 E, left). As expected, there was 
no increase in lymphocyte entry into nondraining brachial 
lymph nodes (Fig. 6 E, right). The results were similar 
for CD8+ T cells and B220+ B cells (unpublished data). 
  Although we have not ruled out that the increased entry at 
day 8 is caused solely by increased endothelial cell activation, 
our   results are consistent with the model that endothelial cell 
growth generated an increased number of entry points for 
circulating lymphocytes.
DCs increase VEGF levels in the lymph node
To examine whether VEGF could be playing a role in our 
system, we assayed for VEGF expression by ELISA. VEGF 
was detectable in quiescent lymph nodes (Fig. 7, A and B), 
but expression levels were only 10% of the level found in an 
equivalent mass of lung (not depicted). Upon subcutaneous 
injection of OVA/CFA, VEGF levels were increased in the 
draining lymph nodes by 24 h and remained elevated for at 
least 5 d (Fig. 7 A). Injection of granulocyte-depleted BMDCs 
led to a similar increase in lymph node VEGF levels, suggest-
ing that DCs were suffi   cient to drive increases in VEGF levels 
and that DCs may stimulate endothelial cell proliferation by 
increasing lymph node VEGF levels (Fig. 7 B). VEGF eff  ects 
are quite sensitive to modest changes in VEGF levels, as even 
heterozygous VEGF gene deletion leads to embryonic death 
(51, 52). Also, a 40–65% decrease in VEGF in the nervous 
system was associated with substantial perinatal lethality and 
a neurodegenerative phenotype (53). The increase in lymph 
node VEGF suggested that VEGF could be an important 
  mediator of DC-induced endothelial proliferation.
To assess the importance of VEGF, we treated mice with 
anti-VEGF antibody and stimulated lymph nodes with gran-
ulocyte-depleted BMDCs. Anti-VEGF signifi  cantly reduced 
the lymph node endothelial cell proliferation (Fig. 7 C). Our 
results suggested that VEGF was critical for stimulating endo-
thelial cell proliferation in activated lymph nodes.
We assessed the eff  ect of depleting DCs on VEGF levels. 
Without DT treatment, immunized wild-type and CD11c-
DTR mice had similar levels of lymph node VEGF (wild-
type, 6.1 ± 1.3 pg/node; and CD11c-DTR, 5.9 ± 1.8 
pg/node; n = 12; P = 0.63 with the paired Student’s t test). 
However, upon DT treatment, VEGF levels in CD11c-DTR 
mice were reduced when compared with the levels in wild-
type mice (Fig. 7 D). This was consistent with the hypothesis 
that DCs were important for inducing increased VEGF levels 
in stimulated lymph nodes and also supported the notion that 
DCs mediated endothelial cell growth, at least in part, by 
  increasing lymph node VEGF levels.
We examined VEGF levels in RAG1−/− mice.  Consistent 
with the intact stimulation of endothelial cell proliferation in 
Figure 7.  Modulation of VEGF levels in draining lymph nodes. 
(A and B) VEGF levels in lymph nodes at days 1, 2, and 5 upon injection with 
either OVA/CFA (A) or 106 granulocyte-depleted BMDCs (B). n = 4 mice 
for each condition. *, P < 0.02 with the Student’s t test compared with 
control mice injected with PBS. (C) Effect of anti-VEGF on lymph node 
endothelial cell (EC) proliferation. Mice were treated with PBS (−), control 
antibody (IgG), or anti-VEGF (αVEGF) and were injected with 106 granulo-
cyte-depleted BMDCs. Endothelial cell BrdU uptake was examined at day 2. 
n = 4. **, P < 0.002. (D) Effect of DC reduction on lymph node VEGF 
  levels. DT-treated wild-type or CD11c-DTR (DTR) mice were immunized 
with OVA/CFA and examined on day 1. n = 12 mice for each condition. 
*, P < 0.05 with the paired Student’s t test. (E) Lymph node VEGF levels 
in RAG1−/− (KO) versus wild-type mice injected with 106 granulocyte-
depleted BMDCs and examined on day 1. n = 9. *, P < 0.05 with the 
 Student’s  t test. (F) Effect of L-selectin blockade on lymph node VEGF 
levels. Mice were treated with anti–L-selectin (αLsel) or control IgG (IgG), 
injected with the indicated number of BMDCs, and examined on day 2. 
n = 6. *, P < 0.02. Error bars represent SD.1910  LYMPH NODE VASCULAR GROWTH | Webster et al.
RAG1−/− mice, VEGF levels also increased from the base-
line in RAG1−/− mice injected with granulocyte-depleted 
BMDCs (Fig. 7 E). Similar to the lower absolute level of en-
dothelial cell proliferation in RAG1−/− mice, the absolute 
level of VEGF was lower when compared with wild-type 
nodes (Fig. 7 E).
We asked whether BMDCs could be a direct source of 
VEGF by examining VEGF expression in BMDCs and by 
examining the role of recruited cells. We detected 2.7 × 
10−6 pg/cell (± 0.8; n = 3) VEGF in granulocyte-depleted 
BMDCs. Although this value does not necessarily refl  ect the 
amount of VEGF secreted over time, the low level of VEGF 
produced by BMDCs suggested that they were unlikely to be 
the source of increased VEGF in stimulated nodes. We also 
examined the eff  ect of L-selectin blockade on VEGF levels. 
Despite the equivalent accumulation of BMDCs in control 
and anti–L-selectin–treated mice (Fig. 5 B), the increase in 
VEGF was abrogated in the anti–L-selectin–treated mice 
(Fig. 7 F). This result further supported the notion that the 
injected DCs were unlikely to be the source of the increased 
lymph node VEGF. Instead, the data indicated that recruited 
cells either expressed VEGF or induced increased VEGF ex-
pression by other cell types. Together, our data suggested 
that DCs stimulate lymph node vascular growth by inducing 
increased VEGF levels in a manner that was dependent on 
cell recruitment.
DISCUSSION
Based on our results, we propose a model whereby DCs, after 
stimulation in the periphery and migration to the lymph 
node, initiate vascular growth in the lymph node. They in-
duce endothelial cell proliferation, at least in part, by induc-
ing the entry through HEVs of circulating cells that increase 
lymph node VEGF levels and stimulate endothelial cell pro-
liferation. The expansion of HEV endothelial cells results in 
increased cell entry and access of circulating cells to the stim-
ulated lymph node, and the expansion of the vasculature in 
general results in the increased delivery of oxygen and micro-
nutrients to meet the increased metabolic needs of the grow-
ing lymph node. Their role in inducing vascular growth in 
the draining lymph node suggests that DCs, in addition to 
presenting antigen, function in part to create a permissive 
  environment for the ensuing immune response.
Our investigation of lymph node vascular growth also re-
vealed a complex role for DCs in the control of lymph node 
growth. Subcutaneous injection of DCs can induce altera-
tions in cell traffi   cking and lymph node growth even within 
1 d (43, 47), which precedes the onset of endothelial cell 
proliferation. In our experiments, the reduced size of the 
stimulated lymph nodes in DC-depleted mice supports the 
notion that DCs are important in inducing very early changes 
in cell traffi   cking. Our studies also suggested that by inducing 
early traffi   cking changes, DCs can potentially regulate cell 
traffi   cking in a less immediate, slower way by inducing the 
growth of the vasculature over time. The two ways of con-
trolling cell recruitment may correspond to the need to recruit 
diff  erent cell types as the immune response progresses. This is 
supported by the observation that NK cell recruitment from 
the bloodstream occurs within 1 d and peaks rapidly at day 2. 
The NK cells are thought to provide an early source of IFN-
γ that is needed to polarize the T cell response (47). NK cells 
may be representative of a cell type that is required for the 
initial stages of the immune response and is recruited by the 
early mechanism that does not depend on endothelial cell 
proliferation. In contrast, although there is an increase in 
lymphocyte recruitment within 1 d (unpublished data), our 
results show that lymphocyte recruitment continues to in-
crease over time. Indeed, three decades ago, a study proposed 
that the increased blood fl  ow in the draining lymph node had 
two phases: a transient early phase followed by a slower onset 
sustained phase that the investigators attributed to angiogen-
esis (14). Our study in conjunction with other recent studies 
would suggest that the fi  rst phase begets the second phase and 
that DCs drive the process.
As our data suggested that DCs stimulate increased VEGF 
and subsequent endothelial cell proliferation in part by re-
cruiting blood-borne cells into the lymph node, it will be 
important to identify the relevant recruited cells in future 
work. Because lymphocytes enter the lymph node in great 
numbers and VEGF levels were reduced in RAG1−/− mice, 
lymphocytes may be an important recruited cell type. B cells 
in the lymph node have been reported to express VEGF after 
immunization (20), suggesting that lymphocytes, when pre-
sent, may contribute directly to increased lymph node VEGF. 
However, DCs were able to stimulate both increased VEGF 
levels and endothelial cell proliferation from the baseline in 
RAG1−/− mice, suggesting that nonlymphocyte cell types 
also contribute. Monocytes can express VEGF (54), can 
be proangiogenic (55–57), and can accumulate in immune-
stimulated nodes (58), suggesting that they may also contribute 
to increased VEGF expression and vascular growth. Finally, 
we have found that resident cells in the lymph node express 
VEGF (unpublished data), and recruited cells may serve 
to stimulate resident macrophages or mesenchymal cells to 
express VEGF.
A study recently showed that B cells regulated lymph 
node lymphangiogenesis and DC migration from the periph-
ery in a manner dependent on B cell entry into the lymph 
node (20). The reduced accumulation of DCs in RAG1−/− 
mice and with L-selectin blockade in our experiments is con-
sistent with their model that B cells regulate DC entry. Taking 
this study into account with our results showing that DCs 
drive lymph node blood vessel growth and increased cell re-
cruitment, we propose that there are two positive feedback 
loops: (a) DCs induce the recruitment of blood-borne cells 
that feedback to positively regulate DC accumulation, and 
(b) the vascular expansion induced by DCs results in the fur-
ther recruitment of circulating cells, which may amplify vas-
cular expansion directly and also indirectly by increasing the 
accumulation of DCs. These feedback loops may serve to 
coordinate the strength of the immunogenic stimulus at the 
periphery (refl  ected by the number of DCs that migrate to JEM VOL. 203, August 7, 2006  1911
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the lymph node), the degree of lymphocyte recruitment 
needed to mediate the immune response, and the degree of 
vascular expansion required to support the increased cell re-
cruitment and metabolic demands.
Our results may have implications for controlling the un-
desired immune responses of autoimmune diseases. Reducing 
endothelial cell growth can potentially limit the magnitude of 
the autoimmune response by decreasing the recruitment of 
circulating cells and limiting the delivery of oxygen and mi-
cronutrients. Identifi  cation of the mediators of DC-driven 
endothelial cell growth will aid in the development of tar-
geted therapies.
MATERIALS AND METHODS
Mice. Unless otherwise specifi  ed, C57BL/6 mice aged 6–12 wk from The 
Jackson Laboratory, Taconic Farms, or National Cancer Institute were used. 
CD11c-DTR and RAG1−/− mice on a B6 background were obtained from 
The Jackson Laboratory. All animal procedures were performed in accor-
dance with the regulations of the Institutional Animal Use and Care Com-
mittee at the Hospital for Special Surgery.
Immunization with OVA/CFA. 1 mg/ml OVA (Sigma-Aldrich) was 
emulsifi  ed in CFA (Sigma-Aldrich), and either 100 μl total was injected in 
three areas in the back or 20 μl was injected per footpad. For the CD11c-
DTR experiments, mice received 100 μg DT (Sigma-Aldrich) in PBS in the 
footpad followed by OVA/CFA 6–8 h later.
Quantitation of lymph node vascularity. Mice were injected intrave-
nously with 100 μg FITC-conjugated tomato lectin (Vector Laboratories) 
and were killed 3 min later. Lymph nodes were fl  ash frozen, and 7-μm 
cryosections were taken every 28 μm through the thickness of the node. 
The area of each section covered by blood vessels was measured by quanti-
tating the fl  uorescence as a pixel count using the Image J digital imaging 
program (National Institutes of Health [NIH]; http://rsb.info.nih.gov/ij/). 
The cumulative area of all of the sections from each lymph node yielded 
a measure of vascularity.
Quantitation of HEV BrdU uptake using immunohistochemistry. 
Mice were pulsed with an intraperitoneal injection of 2 mg BrdU for 2 h 
before killing. Nodes were fl  ash frozen in a particular orientation. 7-μm 
cryosections were collected every 28 μm until we had cut through the wid-
est part of the lymph node. The three consecutive sections that were from 
the widest part of the node were stained for PNAd (BD Biosciences), CD45 
(BD Biosciences), and BrdU (Invitrogen). Immunohistochemical staining 
was performed essentially as described previously (59). In brief,  sections 
were acetone fi  xed for 10 min at 4°C and stained with primary antibodies, 
alkaline phosphatase, and horseradish peroxidase–conjugated secondary anti-
bodies. The horseradish peroxidase was visualized by developing with di-
aminobenzidine (Pierce Chemical Co.), and the alkaline phosphatase was 
visualized using Naphthol AS-MX phosphate with Fast Blue BB salt (Sigma-
Aldrich). Nuclear material was then exposed, and alkaline phosphatase was 
inactivated by incubating the slides in 1 M HCl at 60°C for 20 min. Bioti-
nylated anti-BrdU antibody was applied followed by streptavidin–alkaline 
phosphatase (Jackson ImmunoResearch Laboratories), and color was devel-
oped using Fast Red TR salt (Sigma-Aldrich). For each section, the number 
of HEVs containing one or more PNAd+, CD45−, or BrdU+ cell was enu-
merated and divided by the total number of HEVs in the section. The value 
from each of the three sections was averaged to generate a value for the par-
ticular lymph node.
DC generation, isolation, and injection. BMDCs were generated using 
a modifi  ed protocol of a previous study (44). In brief, BM cells were cul-
tured at 3 × 105 cells/ml in RPMI supplemented with 10% FCS (Cellgro) 
and 7.5% vol/vol of supernatant from J558L cells expressing GM-CSF (gift 
of R. Clynes, Columbia University, New York, NY). Unless otherwise 
specifi  ed, 0.5 μg/ml LPS (Sigma-Aldrich) was added on day 7 to stimulate 
maturation. BMDCs were harvested on day 8, labeled with 1.7 μM CFSE 
(Invitrogen), washed three times, and injected into the footpads.
For the BMDC fractionation experiments, the MACS system (Miltenyi 
Biotec) of magnetic selection was used. In combination with streptavidin-
conjugated magnetic beads (Miltenyi Biotec), biotinylated Gr-1 antibody 
(BD Biosciences) was used to deplete granulocytes, and biotinylated CD11c 
antibody (BD Biosciences) was used to deplete DCs.
Splenic DCs were isolated from collagenase-digested spleen using the 
CD11c antibody and MACS system positive selection. The CD11c+ and 
CD11c− fractions were collected, labeled with CFSE, and injected into sep-
arate recipients.
Treatment with blocking antibodies. Some mice received intraperito-
neal injections of 100 μg anti–L-selectin (clone MEL-14; American Type 
Culture Collection) or isotype control antibody (Southern Biotechnology 
Associates, Inc.) 4 h before the injection of BMDCs. Polyclonal goat anti-
VEGF (R&D Systems) or control antibody (R&D Systems) was injected 4 h 
before the injection of BMDCs. Mice received 200 μg total (100 μg in-
jected intravenously and 100 μg injected intraperitoneally). This antibody 
has been used by other investigators for in vivo VEGF blockade (60, 61).
Flow cytometry analysis. Lymph nodes or spleens were dissected from 
mice, minced into fi  ne fragments, and digested in RPMI + 0.5% BSA + 
564 U/ml collagenase type II (Worthington Biochemical) + 40 μg/ml 
DNase I (Sigma-Aldrich) for 30 min at 37°C while shaking at 50 rpm. Cell 
suspension was triturated 40 times using a Pasteur pipette, and EDTA was 
added to 10 mM. Cells were additionally incubated at 37°C for 5 min, and 
the suspension was passed through a 70-μm fi  lter, washed, and counted.
For quantifi  cation of endothelial cells, cells were stained with rat anti–
mouse CD45 (30-F11; BD Biosciences) and rat anti–mouse CD31 
(MEC13.3; BD Biosciences). HEVs were identifi  ed by combining the afore-
mentioned stain with rat anti-PNAd (MECA-79) followed by goat anti–rat 
IgM (Jackson ImmunoResearch Laboratories) as a secondary antibody.
For the study of BrdU uptake, unless otherwise specifi  ed, mice re-
ceived intraperitoneal injections of 2 mg BrdU (Sigma-Aldrich) at 24 and 
1 h before killing and were fed water containing 0.8 mg/ml BrdU in be-
tween. Cells were stained according to protocol for the APC BrdU Flow 
Kit (BD   Biosciences) except that anti-BrdU was sometimes anti-BrdU–
  AlexaFluor647 (  Invitrogen). Proliferation was expressed as the percentage of 
the population that was BrdU+. DCs in the CD11c-DTR experiments were 
identifi   ed using anti-IAb (AF6-120.1; BD Biosciences) and anti-CD11c 
(HL3; BD Biosciences).
Lymphocyte homing. Recipient mice received 106 BMDCs at 1 or 8 d 
  before lymphocyte transfer. Lymphocytes were isolated from the spleen by 
extruding cells through a 70-μM mesh fi  lter. Cells were labeled with CFSE, 
and  5 × 107 cells were injected intravenously. Mice were killed 30 min later. 
Lymph nodes were harvested, and cells were extruded through a 70-μM mesh 
fi  lter, counted, and stained for CD4, CD8, and B220 (BD Biosciences).
ELISA for VEGF. Lymph nodes were harvested at the specifi  ed time 
points, weighed, and lysed in lysis buff  er (1% Triton X-100, 1% Na deoxy-
cholate, 0.1% SDS, 0.15 M NaCl, and 0.05 M Tris-HCl, pH 7.4). Lysates 
were subjected to ELISA analysis using a DuoSet mouse VEGF kit (R&D 
Systems) according to the manufacturer’s specifi  cations.
Online supplemental material. Fig. S1 shows lymph node blood vasculature 
upon immunization. Fig. S2 shows the eff  ect of unstimulated cultured DCs 
on lymph node vascular growth. Fig. S3 shows the phenotype and localiza-
tion of accumulated BMDCs in the lymph node. Fig. S4 shows the saturation 
of injected anti–L-selectin antibody at day 2. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20052272/DC1.1912  LYMPH NODE VASCULAR GROWTH | Webster et al.
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